Telomir Pharmaceuticals, Inc. Common StockTELONASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank40
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P40
Within normal range
vs 2Y Ago
-0.6x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
PeriodValue
Q4 2025-29.56%
Q3 2025-33.14%
Q2 202519.31%
Q1 2025-42.48%
Q4 202439.56%
Q3 202434.18%
Q2 202421.48%
Q1 2024-78.38%
Q4 202345.73%
Q3 2023-5866.18%
Q2 202395.44%
Q1 2023-187.63%
Q4 2022-210.44%
Q3 20220.00%
Q2 20220.00%
Q1 20220.00%